Conventional APCs that express MHC class II (MHCII) and co-stimulatory molecules include dendritic cells (DCs) and macrophages. Beyond these conventional APCs, immune stimulatory cells have been more recently shown to extend to a class of atypical APCs, composed of mast cells, basophils, and eosinophils. Here, we describe a unique type of APC, Gr1 −/low CD11b −/low cells with a granularity and size characteristic of myeloid cells and with the ability to present Ag for crosspresentation. These cells constitutively express MHCII and the costimulatory molecules, CD80, CD86, and CD40. They do not express pan markers of myeloid DCs (CD11c), plasmacytoid DCs (Ly6C), or macrophages (F4/80), and their frequency is inversely correlated with myeloid-derived suppressor cells (MDSCs) in tumor-bearing mice. Among splenocytes, they are more abundant than DCs and macrophages, and they exhibit antitumor immune stimulatory function at a steady state without further activation, ex vivo. They are also found within the tumor bed where they retain their immune stimulatory function. Our findings suggest the use of these novel APCs in additional preclinical studies to further investigate their utility in APC-based cancer immunotherapies.
the immunogenicity of the vaccine. Recent studies, therefore, have focused on vaccines that make use of primary DCs. 15 For instance, Sipuleucel-T is the only FDA-approved therapeutic vaccine for metastatic prostate cancer. 16 The vaccine uses readily isolated circulating DCs cultured with prostate tumor Ag and GM-CSF. However, circulating DCs are very rare and tumor-induced immune suppressive cells, such as MDSCs, limit their efficacy in inducing a sustained antitumor immune response. Therefore, there is an urgent need to identify a new class of APC that are highly efficient in orchestrating profound antitumor immunity to facilitate the development of a new class of cell-based cancer vaccines.
In recent years, there has been a rapid increase in our understanding of the biology of cells with APC characteristics, namely the ability to activate T cells. For instance, mouse neutrophils can induce Th1 and Th17 responses 17, 18 and tumor-associated neutrophils have been demonstrated to stimulate T cell responses in early-stage human lung cancer. 19 A recent review discusses a number of atypical APCs including mast cells, basophils, eosinophils, and innate lymphoid cells (ILC). 20, 21 However, these APCs are rare in the circulation and their maintenance of effective antitumor immune responses is likely to be inhibited due to high frequencies of MDSCs in locations of T cell priming. Very recently, it was reported that activated NKT cells decrease the frequency and immunosuppressive activity of MDSCs in tumorbearing mice. 22 In an animal model, activated NKT cells converted MDSCs into immunogenic APCs. 23 Using peripheral blood mononuclear cells (PBMC) of patients with early stage breast cancer, we also demonstrated that conversion of MDSCs to CD33 + CD11b −/low HLA-DR + APCs, in vitro, was associated with an increased frequency of CD25+ NKT cells in reprogrammed immune cells. 24 In an effort to understand this MDSC-APC axis during the application of adoptive immunotherapy (AIT) to treat breast cancer, we identified a class of Gr1 −/low CD11b −/low MHCII+ APCs. These cells retain their immune stimulatory function during tumor progression and are inversely correlated to the frequency of splenic and tumorinfiltrating MDSCs. Importantly, we identified the presence of these cells in nonpathological conditions, whereupon we confirmed their ability to cross-present Ag to stimulate T cells. Therefore, these APCs offer a potentially novel APC-based vaccine for cancer therapy.
MATERIALS AND METHODS

Mouse model
FVBN202 transgenic female mice (The Jackson Laboratory; Bar Harbor, ME) were used between 8 and 12 weeks of age throughout these experiments. These mice overexpress a nonmutated, nonactivated rat neu transgene under the regulation of the mouse mammary tumor virus promoter. 25 These mice develop premalignant mammary hyperplasia similar to ductal carcinoma in situ prior to the development of spontaneous carcinoma. 26 Premalignant events in FVBN202 mice include the accumulation of endogenous MDSCs. 26 These studies have been reviewed and approved by the Institutional Animal Care and Use Committee at Virginia Commonwealth University.
Tumor cell lines
The neu overexpressing mouse mammary carcinoma (MMC) cell line was established from a spontaneous mammary tumor harvested from FVBN202 mice. Tumor cells were maintained in RPMI 1640 supplemented with 10% FBS.
Ex vivo reprogramming and expansion of splenocytes
Reprogramming of tumor-sensitized immune cells was performed as previously described by our group. 5 Briefly, FVBN202 transgenic mice were inoculated in the mammary fat pad with 3 × 10 6 MMC cells.
Tumor growth was monitored by digital caliper, and tumor volumes were calculated by volume (v) = (L [length] × W [width] 2 )/2. As previously described, 11 splenocytes were harvested 21-25 days after tumor challenge, when the tumor had reached ≥ 1000 mm. 3 Splenocytes were then cultured in complete medium (RPMI 1640 supplemented with 10 % FBS, L-glutamine (2 mM), 100 U/ml penicillin, and 100 g/ml Streptomycin) and were stimulated with Bryostatin 1 (2 nM; Sigma, Saint Louis, MO), Ionomycin (1 M; Calbiochem, San Diego, CA), and 80 U/ml/10 6 cells of IL-2 (Peprotech) for 16-18 h. 24, 27 Lymphocytes were then washed thrice and cultured at 10 6 cells/ml in complete medium with IL-7 and IL-15 (20 ng/ml of each cytokine, Peprotech, Rocky Hill, NJ). After 24 h, 20 U/ml of IL-2 was added to the complete medium. The following day, the cells were washed and cultured at 10 6 cells/ml in complete medium with 40 U/ml of IL-2.
After 48 h, cells were washed and cultured at 10 6 cells/ml in complete medium with 40 U/ml of IL-2. After 24 h, lymphocytes were again washed and cultured at 10 6 cells/ml in complete medium with 40 U/ml of IL-2. Lymphocytes were harvested 24 h later on the sixth day and were then either used in AIT or analyzed ex vivo. Reprogramming of splenocytes consistently yielded 5-fold expansion with greater than 40% memory T cells and 35% CD25+ NKT cells. 27 
Adoptive cellular therapy
Twenty-four hours prior to AIT, FVBN202 mice were injected i.p. with CYP (100 mg/kg) to induce lymphopenia. Approximately 18 h later FVBN202 mice were challenged i.v. with MMC cells (1 × 10 5 ). Mice then received adoptive transfer of reprogrammed splenocytes i.v. at a dose of 70 × 10 6 /mouse later the same day (AIT), or remained untreated (Control). The study end-point and euthanasia occurred when the animals were considered moribund upon losing 10-20% of their initial body weight due to disease progression.
Characterization of splenocytes and tumor-infiltrating leukocytes
Spleens and metastases of tumor-bearing FVBN202 mice were harvested when the animals became moribund, and were then homogenized into a single cell suspension as described previously 28 and below; single cell suspensions were then characterized using flow cytometry.
Reagents used for flow cytometry: anti-CD16/32 Ab (93); FITC-CD11b (M1/70); PE-GR-1 (RB6-8C5); PE-CD11c (N418); PE-F4/80 (BM8); PE-CD25 (3C7); Allophycocyanin-CD49b (DX5); Allophycocyanin-Annexin V; Alexa Fluor 647-I-Aq (KH116); Alexa Fluor 700 Ly-6G (1A8); PercP/CY5.5-CD86 (GL-1); PercP/CY5.5-Rat IgG2a, k Isotype Control (RTK2758); PE-Dazzle-CD80 (16-10A1); PE-Dazzle-Armenian Hamster IgG Isotype Control (HTK888); PE/CY7-CD40 (3/23); PE/CY7-Rat IgG2a, k Isotype Control (RTK2758); Brilliant Violet 510 Ly-6C (HK1.4); Brilliant Violet 605-CD45 (30-F11); BV421-CD20 (SA275A11); BV711-Ly6C (HK1.4); BV510-CD11b (M1/70); and BV785-CD86 (GL-1), all of which were purchased from Biolegend (San Diego, CA). BD Horizon V450-Annexin V and BUV395-CD3 (SK7) were purchased from BD Biosciences (Franklin Lakes, NJ).
Propidium Iodide (PI) was purchased from Sigma. (All reagents were used at the manufacturer's recommended concentration. Cellular staining was performed as previously described by our group. 24 Multicolor data acquisition was performed using a LSRFortessa X-20 (BD Biosciences) and a ImageStreamX Mark II Imaging Flow Cytometer (Millipore Sigma, Billaerica, MA). Data was analyzed using FCS Express v4.07 and v5.0 (De Novo Software; Glendale, CA).
Sorting of myeloid cells by FACS
Splenocytes were stained for surface expression of CD11b and Gr1 as described above. Isolated cells were gated on the myeloid cell population based on their inherent light scattering properties 29 thereby excluding cells of lymphoid origin. Gr1 −/low CD11b −/low myeloid cells from the Control and AIT groups were then sorted into independent populations using a FACSAria (BD Biosciences) as previously described. 30 Purity of sorted cells was consistently greater than 90%.
IFN-ELISA
Splenocytes from the Control and AIT groups were independently cultured in serum-free RPMI 1640 in order to enrich for nonadherent cells. 31 After 2 h, nonadherent lymphocytes were cultured in complete medium with irradiated MMC cells (140 Gy) at a 10:1 ratio, and with or without sorted Gr1 −/low CD11b −/low myeloid cells at a 2:1 ratio, for Supernatants were then collected and stored at −80 • C until assayed.
IFN-was detected in the supernatant using a Mouse IFN-ELISA kit (BD Biosciences), according to the manufacturer's protocol.
In vitro Ag uptake
Splenocytes (10 6 cells/ml) of naïve FVBN202 mice were pulsed with 50 ug/ml Alexa Fluor 488 (AF488)-conjugated ovalbumin (Ther-moFisher Scientific) in RPMI1640 supplemented with 10% FBS for 5 or 16 h. Cells were then washed and stained for FVS, CD11c, CD11b, Gr1. Gated FVS-viable cells were subgated for CD11c+ DCs or Gr1 −/low CD11b −/low myeloid cells, and analyzed for Alexa Fluor 488 as a reporter of OVA internalization.
Cytotoxicity assay
Antitumor efficacy of T cells was determined in a cytotoxicity assay, in vitro, using flow cytometry as previously described by our group 32 with minor modifications. The ex vivo expanded tumor reactive T cells were cultured in complete medium with MMC cells (10:1 E:T ratio) in the presence or absence of sorted Gr1 −/low CD11b −/low cells at a 5:1 ratio (five T cells vs. one APCs), for 48 h. Cells were collected and stained with Annexin V, PI, anti-CD45 and anti-Neu Abs immediately prior to flow cytometry acquisition.
Isolation of tumor-infiltrating leukocytes from lung metastases
Lungs were harvested from the Control and AIT groups after animals became moribund. Metastatic lesions were individually excised from the residual lung tissue, and were minced and digested in Trypsin-EDTA (0.25%; Life Technologies) overnight at 4 • C. The following day, the suspension was incubated at 37 • C for 30 min, followed by gentle tissue homogenization to create a cellular suspension. The cell suspension was then washed twice with RPMI supplemented with 10% FBS. Residual red blood cells were then lysed using ACK lysing buffer, followed by an additional wash with RPMI 10% FBS. 10 6 cells of the suspension were then stained for surface molecules as described above. All analysis was performed by gating on viable leukocytes (CD45+ Annexin V − ).
Statistical analysis
Outcomes are summarized by basic descriptive statistics such as mean and SEM; differences between groups are illustrated using graphical data presented as mean ± SEM. Statistical comparisons between groups were made using one-tailed and two-tailed Student's t-test per the specific hypothesis. Time to death in the in vivo survival studies was calculated from baseline to the date of death. Mice were euthanized when they had a weight loss of ≥10%. Kaplan-Meier curves and log-rank tests are used to illustrate time to death and to test the difference between each group. A P-value ≤ 0.05 was considered statistically significant.
RESULTS
Gr1 −/low CD11b −/low cells demonstrate characteristics of professional APCs
Antitumor immune responses are often corrupted in tumor bearing hosts due to pathological emergency myelopoiesis, which leads to the accumulation of MDSCs in secondary lymphoid organs and tumor beds. 33, 34 However, it has been reported that lymphoid effectors, namely NKT cells, functionally alter MDSC function by promoting an immunostimulatory, rather than suppressive, phenotype in the context of antitumor immunity. 24, 27 Therefore, we sought to gain an
F I G U R E 1 Splenic Gr1 −/low CD11b −/low cells show characteristics of APCs. (A)
Splenocytes of naïve FVBN202 mice (n = 3) were gated within the myeloid cell region based on forward-scatter and side-scatter, and were analyzed for the expression of Gr1 and CD11b. The proportion of the splenic Gr1 −/low CD11b −/low myeloid cells and Gr1 + CD11b + myeloid cells was determined. (B) Gated Gr1 −/low CD11b −/low cells were analyzed for the expression of MHC class II (MHCII). Gated Gr1 −/low CD11b −/low MHCII + cells were also analyzed for the expression of the co-stimulatory molecules, CD80, CD86, and CD40. Mean fluorescence intensity (MFI) of the co-stimulatory molecules showed a significant shift compared with isotype control. (C) Sorted Gr1 −/low CD11b −/low MHCII + cells were cultured in the absence (-LPS) or presence of LPS (+LPS, 1 g/ml) for 24 h. Gated Gr1 −/low CD11b −/low MHCII + cells were analyzed for the expression of MHCII as well as CD80, CD86, or CD40. MFI was calculated after the subtraction of isotype control. (MFI: 488 vs. 800, P = 0.001). Despite displaying such classical characteristics of APCs, Gr1 −/low CD11b −/low cells did not express pan markers of DCs, CD11c, or macrophages, F4/80 ( Fig. 1D ). Importantly, however, these Fsc hi Ssc hi Gr1 −/low CD11b −/low myeloid cells possess a similar size and granularity, and express similar levels of MHCII as well as costimulatory molecules to total splenic macrophages and dendritic cells ( Supplementary Fig. 1 ). The total frequency of Fsc hi Ssc hi Gr1 −/low CD11b −/low APCs was significantly higher than all DCs and macrophages in the spleen ( Fig. 1E , P = 0.008 and P = 0.04, respectively). Additionally, morphological studies of these cells using Diff-Quick staining demonstrated the presence of both monoblast-like (large cells), and lymphocyte-like (small cells) within the Fsc hi Ssc hi Gr1 −/low CD11b −/low gate ( Supplementary Fig. 2 ).
Given that Diff-Quick staining revealed the presence of lymphocyte-like cells among sorted Gr1 −/low CD11b −/low cells from naïve mice, we sought to further determine the phenotype 
Gr1 −/low CD11b −/low MHCII + cells are heterogeneous populations that are both lineage committed and noncommitted
To further unravel the biology of Gr1 −/low CD11b −/low MHCII + cells, we found that approximately 50% of these cells expressed Ly6G, indicative of a commitment to the granulocyte lineage, while the remainder of this population was negative for both Ly6G and Ly6C (Fig. 3A) . Accordingly, the Ly6G + Ly6C − subset displayed a more mature phenotype than the Ly6G − Ly6C − subset, expressing significantly higher levels of MHCII (P = 0.001), CD80 (P = 0.03), CD86 (P = 0.0006), and CD40 (P = 0.025; Fig. 2B ). As the Ly6G − Ly6C − subset did not demonstrate a specific myeloid-cell lineage commitment by any parameter that we tested, we hypothesized that this population would respond more robustly to activating stimuli due to a presumed lack of maturity. Indeed, as shown in Fig. 3C , the Ly6G − Ly6C − subset showed a stronger response to LPS stimulation when compared to vehicle treatment than the Ly6G + Ly6C − subset. This suggests that under nonpathological conditions there exists a population of both lineage committed and noncommitted splenic Gr1 −/low CD11b −/low MHCII + cells, which possess the potential to perform professional Ag-presenting cellular functions.
Adoptive immunotherapy modulates Gr1 −/low CD11b −/low APCs
It has been reported that activated NKT cells can convert MDSCs into immune-stimulatory APCs. 22, 23 We have reported that reprogrammed lymphocytes containing CD25+ NKT cells can induce maturation of human CD33 + CD11b + HLA-DR − MDSCs into stimulatory CD33 + CD11b −/low HLA-DR + APCs, in vitro. 24, 27 Given the inverse correlation between Gr1 + CD11b + cells and Gr1 −/low CD11b −/low APCs in naïve mice (Fig. 1A) , we sought to determine the impact of tumor burden as well as AIT, containing conventional tumor-specific T cells and CD25+ NKT cells, on the modulation of Gr1 −/low CD11b −/low APCs, in vivo. FVBN202 mice were challenged i.v. with Neu-overexpressing MMC tumor cells, and then either remained untreated (control) or were subjected to an adoptive transfer of tumor-sensitized reprogrammed T cells and NKT cells. 32 Animals were sacrificed upon disease progression culminating in metastases in the lung. As shown Supplementary Fig. 3 , P = 0.037). Further analyses showed similar levels of MHCII expression (MFI and % gated) in both groups, though those treated with AIT had a significantly higher frequency of Gr1 −/low CD11b −/low MHCII + APCs among all splenocytes ( Fig. 4C , P = 0.001). AIT also resulted in the up-regulation of CD86 (Fig. 4D , MFI: 32 vs. 66, P = 0.01) and down-regulation of CD40 (Fig. 4D, 616 vs. 278, P = 0.001) on Gr1 −/low CD11b −/low cells. In fact, AIT restored the frequency of Gr1 −/low CD11b −/low MHCII + APCs and the expression of CD40 to the levels similar to those in naive mice, though CD86 expression was uniquely up-regulated following AIT ( Supplementary Fig. 4A ).
AIT also resulted in a significantly increased frequency of splenic CD11c + DCs and F4/80 + macrophages ( Supplementary Fig. 4B , P = 0.001 and P = 0.018, respectively). In order to determine whether As the Ly6G + Ly6C − subset had a higher expression of costimulatory molecules than the Ly6G − Ly6C − subset in naïve mice ( Fig. 3) , we sought to determine whether this trend was also present during tumor burden or following AIT. Subset analysis of Gr1 −/low CD11b −/low APCs showed the emergence of a Ly6G + Ly6C − cell population in tumor-bearing mice that received AIT when compared with the control group (Fig. 5A, 35% vs. 7%). Unlike untreated tumor-bearing mice, animals receiving AIT showed a similar trend with naïve mice in regards to the frequency of Ly6G + Ly6C − myeloid cells ( Supplementary Fig. 5 ). Whereas both subsets showed comparable levels of the expression of MHCII, CD80, and CD40 in the control and AIT groups, the Ly6G + Ly6C − subset exhibited a significantly higher level of CD86 expression ( Fig. 5B , Control, MFI: 17 vs. 27; AIT, MFI: 16 vs. 41). As expected, the mature Ly6G + Ly6C − subset did not result in an increase in the expression of CD86 following LPS stimulation. However the Ly6G − Ly6C − subset in the control group and F I G U R E 4 Continued (E) Gr1 −/low CD11b −/low cells were sorted from the spleens of the AIT and control groups and cultured for 24 h in the presence or absence of LPS (+LPS and -LPS). Gated cells were then analyzed for the expression of MHCII and co-stimulatory molecules. Data represent mean ± SEM of triplicate experiments in the AIT group did experience increases in the expression of CD80 ( Fig. 4C , P = 0.042 and P = 0.058) and CD86 ( Fig. 4C , P = 0.004 and P = 0.058). The Ly6G − Ly6C − subset within control mice also increased the expression of MHCII (P = 0.021) and CD40 (P = 0.05) following LPS stimulation. Therefore, these data suggest that AIT rescues the myeloid compartment of tumor-bearing animals by promoting the maturation of myeloid cells to the frequency and functional potential observed in naïve mice.
Gr1 −/low CD11b −/low Ly6G + Ly6C − APCs are present within the tumor bed
To determine whether Gr1 −/low CD11b −/low APCs are present in the tumor bed, tumor lesions of both the AIT and control groups were analyzed when animals were euthanized due to tumor progression with similar tumor burden. As in the spleen, we again found that Gr1 −/low CD11b −/low cells dominated the tumor-infiltrating Fsc hi Ssc hi myeloid cell compartment within the AIT group, where they demonstrated a greater than 3-fold increase in frequency over Gr1 + CD11b + MDSCs ( Supplementary Fig. 6A, 14% vs. 46%, p = 0.016). Such differences were, again, not observed in the control group, These Gr1 −/low CD11b −/low APCs had similar pattern of maturation between the AIT and control groups to that of the spleen, as shown by comparable levels of the expression of MHCII, CD80, CD86, and CD40 ( Supplementary Fig. 6B ). Within the tumor bed, the Ly6G + Ly6C − subset was clearly dominant within the AIT group (Supplemental Fig. 6C , 63% vs. 16%; P = 0.014). Whereas both subsets showed comparable levels of costimulatory molecule expression, the Ly6G + Ly6C − subset demonstrated more robust MHCII expression at the tumor site of the AIT group ( Supplementary Fig. 6D , MFI: 11984 vs. 4739, P = 0.026).
Gr1 −/low CD11b −/low APCs exhibit immune stimulatory function
In order to determine if Gr1 −/low CD11b −/low APCs possess immune stimulatory function during tumor burden and/or following AIT, splenic lymphocytes from the AIT and control group were independently cultured with MMC tumor cells in the presence or absence of sorted autologous Gr1 −/low CD11b −/low cells. As shown in Fig. 6A, lym- phocytes derived from the AIT group released IFN-in the presence of Neu + MMC cells (p = 0.0001). Importantly, the IFN-producing immune response to MMC was significantly boosted by autologous Gr1 −/low CD11b −/low APCs (Fig. 6A , p = 0.015). On the other hand, lymphocytes derived from the control group did not demonstrate significant IFN-release in the presence of MMC; the addition of autologous Gr1 −/low CD11b −/low APCs did not enhance this response (Fig. 6B) . In order to determine if Gr1 −/low CD11b −/low myeloid cells from the control group retained their immune stimulatory function, they were co-cultured with tumor-reactive T cells from the AIT group in the presence or absence of MMC. We hypothesized that T cell specific killing of MMC cells from the AIT group could facilitate cross presentation of tumor Ags by Gr1 −/low CD11b −/low APCs, resulting in the enhancement of the immune response. As shown in Fig. 6C , the presence of Gr1 −/low CD11b −/low APCs boosted tumor-reactive IFNproduction by splenic T cells derived from the AIT group (P = 0.0002).
This was associated with the induction of apoptosis in MMC by
reprogrammed T cells that were used for AIT compared with those of the control group ( Fig. 6D , P = 0.0004). To assess the possibility of Gr1 −/low CD11b −/low myeloid cells to potentially uptake and cross-present Ag to T cells, we first pulsed these cells with ovalbumin conjugated to a fluorophore. As shown in Fig. 6E , Gr1 −/low CD11b −/low myeloid cells demonstrated the ability to uptake this protein, with increased fluorescence intensity over time. Although it appears these cells have a reduced efficiency to uptake this Ag compared to DCs, these data suggest that Gr1 −/low CD11b −/low myeloid cells may potentially function to cross-present processed Ag to T cells. Neu ECD protein, followed by a culturing period with tumor-sensitized T cells. In fact, as can be seen in Fig. 6F , Gr1 −/low CD11b −/low myeloid cells were able to induce IFN-production from tumor-sensitized T cells only after they were pulsed with Neu ECD, suggesting these cells possess Ag-processing and presentation functionality. Bone marrowderived DCs were used a positive control for Ag cross presentation;
irradiated MMC cells were used as a specificity control for assessing Neu-reactive T cell function. We then utilized a direct cytotoxicity assay to demonstrate that sorted Gr1 −/low CD11b −/low myeloid cells from tumor-bearing mice boosted tumor-reactive T cell-mediated killing of MMC target cells, ex vivo ( Fig. 7A, P = 0.001) . These data suggest that although tumor burden drives the expansion of MDSCs and suppresses the expansion of mature Ly6G + Ly6C − APCs, these Gr1 −/low CD11b −/low cells retain their immune stimulatory function, but may not become fully functional in the presence of a weak antitumor immune response.
DISCUSSION
Here, we describe a new class of APC, Gr1 −/low CD11b −/low cells that do not express pan markers of myeloid DCs (CD11c), plasmacytoid DCs (Ly6C) or macrophage (F4/80). Characterization of these cells demonstrated their expression of MHCII and the costimulatory molecules CD80, CD86, and CD40 at the steady state. Further characterization of this population revealed that while the majority of Gr1 −/low CD11b −/low myeloid cells do not express T or B cell lineage markers, we found that B cells interact with this myeloid APC population, a phenomenon that has classically been described to occur between DCs and B cells. 35, 36 This interaction may contribute to the immune stimulatory function of these atypical APCs, as such an interaction has been reported to boost immune stimulatory function of conventional DCs. 37 The frequency of Fsc hi Ssc hi Gr1 −/low CD11b −/low
APCs was significantly greater than that of DCs in the spleen. Importantly, Gr1 −/low CD11b −/low APCs were also present at the tumor site of animals bearing lung metastases at a frequency that was inversely proportional to that of MDSCs. Interestingly AIT drove the 39 and in vitro. 40 Similar MDSC-mediated suppressive function of macrophages has been reported in cancer patients. 41 Furthermore, DC-intrinsic immune suppressive activity has been reported in cancer patients as well as in animal models of transplanted and spontaneous carcinoma. [42] [43] [44] [45] [46] In summary, we have identified Gr1 −/low CD11b −/low myeloid cells that possess characteristics of APCs that are unique in the following ways: (i) they are more abundant than DCs, (ii) they are heterogeneous making them highly effective in both Ag uptake and We thank Julie Farnsworth and Qingzhao Zhang of Virginia Commonwealth University for their assistance with cell sorting. We also thank Dr. Jose R. Conejo-Garcia for graciously providing key reagents.
